Sep 2025 (Q3 FY25) — Oct 30, 2025
argenx SE Q3 FY25 — VYVGART tops $1B in a single quarter as pipeline swells to 3 Phase III assets
Read the full callargenx SE (ARGX) earnings
- Sep 2025 (Q3 FY25)
argenx SE earnings: last reported Thu, 30 Oct 2025, for the quarter ended Sep 2025.
Price
$825.61 +0.79% · +$6.47
Performance −2.1% 1Y
1Y: $843.66 on 17 Oct 2025 → $825.61. High $1,058.9 (27 Aug 2026), low $663.93 (20 Mar 2026).
- Previous close
- $819.14
- 52-week range
- $663.93 – $1,058.9
- One year
- −2.81%
Overview
- Symbol
- ARGX
- Sector
- Health Care
- Industry
- Biological Products, (No Diagnostic Substances)
- Exchange
- US
- Currency
- USD
Call summaries
Jun 2025 (Q2 FY25) — Jul 31, 2025
argenx SE Q2 FY25 — Strong VYVGART Growth and Pipeline Advancement
Read the full callEvery analysed call
argenx SE earnings calls (ARGX)
Insider filings
No filings in the last 12 months.
No officer, director or 10% owner of ARGX filed a Form 4 in this window. That is a statement about filings, not about ownership — see the note below.
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for ARGENX SE
Free account. Everything above stays public.
Write why you follow ARGENX SE and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading